Skip to main content
Free research Free research Free target review with research home and workspace preview
Quick search ChEMBL 36
Loading Target Snapshot...
Querying ChEMBL database. This may take a few seconds.
Target Snapshot

CHEMBL3290 Target Snapshot

Ephrin type-B receptor 2 · SINGLE PROTEIN · Homo sapiens

1,249Compounds
307Assays
13Approved Drugs
505.0Activities
Free Research Context

Research home keeps recent targets

This target will appear in recent viewed items on this browser. Use the demo workspace to preview watch rules and decision queues.

Navigation

Switch target

Move to another high-traffic target or paste a specific ChEMBL target ID.

Broader Open DB context

Frame the target before identity details

Structured disease, protein, and project context should read before the lower-level identity rail.

As of 2026-09-13

Protein identity stays anchored to UniProt P29323. Use UniProt P29323 as the stable identity anchor, then attach disease evidence before program review.

Review focus
Protein anchor ready

Use UniProt P29323 as the stable identity anchor, then attach disease evidence before program review.

ChEMBL component mapping + Open Targets-ready proxy + ChEMBL 36 via Core Engine 2026-09-13
Open source guide
Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats Ephrin type-B receptor 2 as ChEMBL target CHEMBL3290, mapped to UniProt P29323. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor
Ephrin type-B receptor 2
SINGLE PROTEIN · Homo sapiens
As of 2026-09-13
ChEMBL target ID
CHEMBL3290
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine As of 2026-09-13
www.ebi.ac.uk
UniProt accession
P29323
Ephrin type-B receptor 2
UniProt accession via ChEMBL component mapping As of 2026-09-13
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy As of 2026-09-13
www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Source Guidance

Start with the right source

Choose the first block or source based on the question you are trying to answer.

Need stable target naming and protein identity?
UniProt Target Context
UniProt accession via ChEMBL component mapping

Start here when your first question is whether Ephrin type-B receptor 2 is the right protein anchor across sources, using UniProt P29323 as the stable mapping.

Jump to Protein Context
Need disease fit before discussing compounds?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy

Use this block first when you need the strongest disease program and evidence level in one place.

Jump to Disease Context
Need a meeting-ready explanation of why this target matters?
Evidence Card
Review-ready rationale with source-aware context

Open the one-page evidence card when you want the rationale, activity base, and attribution together.

Open Review-ready Card
Overview

Basic Information

Verify identity, organism, and the fastest next research jumps from the same page.

UniProt Context

UniProt Target Context

Reviewable protein naming and mapping context for this target snapshot.

Protein LabelEphrin type-B receptor 2
UniProt AccessionP29323
Component TypeProtein
Sequence Length1055 aa

Ephrin type-B receptor 2

Source · UniProt accession via ChEMBL component mapping
Review Cue

How to read this target

Review this target as Ephrin type-B receptor 2, mapped to UniProt P29323. Sequence length is 1055 aa.

Mapped IDP29323
Review nameEphrin type-B receptor 2
OrganismHomo sapiens
Clinical Profile

Clinical Phase Distribution

13
Approved
6
Phase III
12
Phase II
4
Phase I
Assay Mix

Activity Type Distribution

IC50104.0
KI4.0
EC503.0
KD394.0
Lead Set

Top Inhibitors (by pChEMBL)

ChEMBL IDpChEMBLTypeValue (nM)Phase
CHEMBL5416410 9.41 Kd 0.39 Approved
CHEMBL566515 8.92 IC50 1.2 Preclinical
CHEMBL400402 8.7 Kd 2.0 Preclinical
CHEMBL3752910 8.6 IC50 2.5 Preclinical
CHEMBL1421 8.57 IC50 2.7 Approved
CHEMBL4568087 8.54 IC50 2.9 Preclinical
CHEMBL1230609 8.41 Kd 3.9 Clinical
CHEMBL1421 8.41 Kd 3.9 Approved
CHEMBL5416410 8.36 IC50 4.4 Approved
CHEMBL249097 8.15 Kd 7.0 Preclinical
Distribution

pChEMBL Value Distribution

23
5.0
24
5.5
18
6.0
10
6.5
13
7.0
8
7.5
9
8.0
6
8.5
2
9.0
0
9.5
pChEMBL
Approved Drugs

Approved Drugs

TIVOZANIB
CHEMBL1289494
Approved 2017
BOSUTINIB
CHEMBL288441
Approved 2012
VANDETANIB
CHEMBL24828
Approved 2011
NILOTINIB
CHEMBL255863
Approved 2007
DASATINIB
CHEMBL5416410
Approved 2006
DASATINIB ANHYDROUS
CHEMBL1421
Approved 2006
Assay Landscape

Assay Landscape

307
Total Assays
112
Tested Compounds
2
Assay Types
Binding — 306 assays, 112 compounds
BAO Format Assays Compounds Avg pChEMBL
single protein format 242 78 6.1
assay format 32 8 7.3
cell-based format 26 7 6.6
subcellular format 6 19 6.2
Functional — 1 assays, 0 compounds
BAO Format Assays Compounds Avg pChEMBL
assay format 1 0

Confidence Score Distribution

Source · ChEMBL 36 via Core Engine